文献速递浆细胞疾病

多发性骨髓瘤患者中卡非佐米的肾脏与心脏并发症

Cardiac and renal complications of carfilzomib in patients with multiple myeloma.
PubMed 文献 · Blood Adv · 2017-02-27

在60例连续接受卡非佐米为基础方案的多发性骨髓瘤患者中,12%出现左心室射血分数可逆性降低≥20%;LVEF降低发生率随时间累积,且既往心血管疾病与心脏事件发生率升高相关但未达统计学显著。卡非佐米常伴估算肾小球滤过率一过性降低,但55%基线eGFR<60 mL/min/1.73 m²者肾功能改善。

要点

  • 60例接受卡非佐米方案患者中12%出现LVEF可逆性降低≥20%,3、6、12、15个月累积发生率分别为5%、8%、10%、12%。
  • 既往心血管疾病与心脏事件发生率升高相关(23.5% vs 7%;P = .07),未达统计学显著。
  • 55%基线eGFR <60 mL/min/1.73 m²的患者肾功能改善,卡非佐米常伴eGFR一过性降低。

核心结论

  • 卡非佐米治疗多发性骨髓瘤患者中,LVEF可逆性降低≥20%的发生率为12%(95%CI 3.8%-20%),需进一步研究阐明卡非佐米相关心肾毒性的机制。

研究设计与样本

  • 对60例连续接受卡非佐米为基础方案的多发性骨髓瘤患者进行心血管危险因素全面评估。

主要发现

  • 12%(95%CI 3.8%-20%)患者出现LVEF可逆性降低≥20%。
  • LVEF降低发生率在3个月为5%、6个月为8%、12个月为10%、15个月为12%。
  • 与毒性无关的卡非佐米停药率在3、6、12、15个月分别为17%、35%、41%、49%。
  • 既往已知心血管疾病与心脏事件发生率升高相关(23.5% vs 7%;P = .07)。
  • 55%基线eGFR <60 mL/min/1.73 m²的患者肾功能改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究阐明卡非佐米相关心肾毒性的潜在机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials with carfilzomib have indicated a low but reproducible incidence of cardiovascular and renal toxicities. Among 60 consecutive myeloma patients treated with carfilzomib-based regimens who were thoroughly evaluated for cardiovascular risk factors, 12% (95% confidence interval, 3.8%-20%) experienced a reversible reduction of left ventricular ejection fraction (LVEF) by ≥20%, an objective measure of cardiac dysfunction. The incidence of LVEF reduction was 5% at 3 months, 8% at 6 months, 10% at 12 months, and 12% at 15 months, whereas the respective carfilzomib discontinuation rate unrelated to toxicity was 17%, 35%, 41%, and 49%. The presence of any previously known cardiovascular disease was associated with an increased incidence of cardiac events (23.5% vs 7%; P = .07), but there was no association with the dose of carfilzomib or the duration of infusion. Re-treatment with carfilzomib at lower doses was possible. Carfilzomib was commonly associated with a transient reduction of estimated glomerular filtration rate (eGFR) but also improved renal function in 55% of patients with baseline eGFR <60 mL/min/1.73 m2. Further investigation is needed to elucidate the underlying mechanisms of carfilzomib-related cardiorenal toxicity.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017. PMID: 29296960. doi:10.1182/bloodadvances.2016003269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。